Hansa Biopharma AB (HNSA, Financials) reported its fourth-quarter and full-year 2024 financial results, highlighting strong growth in IDEFIRIX sales and advancements in its clinic ...

Hansa Biopharma reported its Q4 2024 earnings, revealing a larger-than-expected loss and lower-than-forecast revenue. The company posted an EPS of -4.08, significantly missing the forecast of -1.98, ...